Reduction of matrix metalloproteinase 8-neutrophil collagenase levels during long-term doxycycline treatment of reactive arthritis

Antimicrob Agents Chemother. 1994 Feb;38(2):400-2. doi: 10.1128/AAC.38.2.400.

Abstract

The aim of this work was to determine whether human polymorphonuclear neutrophilic interstitial collagenase (matrix metalloproteinase 8 [MMP-8]) levels are reduced during long-term doxycycline treatment in humans with reactive arthritis. Serum MMP-8 levels were reduced (mean +/- standard error of the mean, 678.9 +/- 185.6 versus 491.2 +/- 144.8 ng of MMP-8 per ml), but not statistically significantly. However, the reduction of salivary MMP-8 levels was statistically significant (3,729 +/- 1,905.3 versus 1,866 +/- 780.0 ng of MMP-8 per ml, P < 0.05). This study demonstrated that a 2-month regimen of doxycycline can reduce MMP-8 levels in serum and especially in body fluids (i.e., saliva) containing inflammatory exudates and thus may contribute to reduced tissue destruction.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Arthritis, Reactive / blood
  • Arthritis, Reactive / drug therapy*
  • Arthritis, Reactive / enzymology*
  • Chlamydia Infections / blood
  • Chlamydia Infections / drug therapy
  • Chlamydia Infections / enzymology
  • Chlamydia trachomatis
  • Collagenases / blood
  • Collagenases / metabolism*
  • Doxycycline / therapeutic use*
  • Drug Administration Schedule
  • Female
  • Humans
  • Male
  • Matrix Metalloproteinase 8
  • Salmonella Infections / blood
  • Salmonella Infections / drug therapy
  • Salmonella Infections / enzymology
  • Yersinia Infections / blood
  • Yersinia Infections / drug therapy
  • Yersinia Infections / enzymology
  • Yersinia enterocolitica

Substances

  • Collagenases
  • Matrix Metalloproteinase 8
  • Doxycycline